COLLEGIUM PHARMACEUTICAL, INC (COLL)

Pharmaceutical Preparations · market cap $734M · as of 2026-07-20

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Collegium Pharmaceutical (COLL) is a ~$1.17B market-cap specialty pharma company with 357 employees, generating $781M in 2025 revenue and $63M net income. Its lead pipeline asset is Oxycodone DETERx (Phase 3, Chronic Low Back Pain), and the company carries net debt of ~$339M against $268.6M cash. A June 2026 acquisition was flagged as a positive recent catalyst.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Oxycodone DETERx	Phase 3	Chronic Low Back Pain

Price & technical context

3-month

-41.0%

6-month

-34.3%

12-month

-37.6%

52-wk range

$21.82–$49.84

vs 50-day MA

-19.2%

vs 200-day MA

-39.1%

Realized vol

44.5%

Max drawdown

-56.2%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for COLL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.